GAP-107B8

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameGAP-107B8
Drug Alias NamePhGa1neuroblastoma therapy (PharmaGap)GAP-43aprotein kinase C alpha inhibitor (PharmaGap)PhGalpha1 +[6] 
ClassificationBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionSerine/threonine-protein kinase mTOR inhibitorsProtein kinase C inhibitorsMitogen-activated protein kinase inhibitors
TargetsMitogen-activated protein kinaseProtein kinase CSerine/threonine-protein kinase mTOR
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanada
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPharmaGap Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPharmaGap Inc
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A